Condition: Advanced Endometrial Carcinoma · Recurrent Endometrial Carcinoma · Sponsor: National Cancer Institute (NCI)
This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with stage III, IVA or IVB mismatch repair protein proficient (pMMR) and TP53 mutated endometrial cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has come back after a period of improvement (recurrent). Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Adding bevacizumab to the combination of carboplatin, paclitaxel and pembrolizumab may be more effective than the usual treatment combinations of carboplatin and paclitaxel with or without pembrolizumab in treating patients with advanced or recurrent pMMR and TP53 mutated endometrial cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Recruiting |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | Recruiting |
| Cancer Center at Saint Joseph's | Phoenix, Arizona, United States | Recruiting |
| Highlands Oncology Group - Fayetteville | Fayetteville, Arkansas, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Highlands Oncology Group - Rogers | Rogers, Arkansas, United States | Recruiting |
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| Mercy Cancer Center - Carmichael | Carmichael, California, United States | Recruiting |
| Mercy San Juan Medical Center | Carmichael, California, United States | Recruiting |
| Mercy Cancer Center - Elk Grove | Elk Grove, California, United States | Recruiting |
| Los Angeles General Medical Center | Los Angeles, California, United States | Recruiting |
| USC / Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
+ 230 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07198074